Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/ehf2.12251 http://scihub22266oqcxt.onion/10.1002/ehf2.12251 C5880656!5880656!29345425     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       ESC+Heart+Fail 2018 ; 5 (2): 337-43 Nephropedia Template TP {{tp|p=29345425|t=2018. Eligibility of sacubitril?valsartan in a real?world heart failure population: a community?based single?centre study |pdf=|usr=}}{{29345425}} gab.com Text Eligibility of sacubitril valsartan in a real world heart failure population: a community based single centre study JO: ESC Heart Fail http://www.kidney.de/pget.php?&tw=1&pmid=29345425 #FOAvip Aims: This study aims to investigate the eligibility of the Prospective Comparison of Angiotensin Receptor?Neprilysin Inhibitor (ARNI) with ACE inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM?HF) study to a real?world heart failure population. Methods and results: Medical records of all heart failure patients living within the catchment area of Umeå University Hospital were reviewed. This district consists of around 150 000 people. Out of 2029 patients with a diagnosis of heart failure, 1924 (95%) had at least one echocardiography performed, and 401 patients had an ejection fraction of ?35% at their latest examination. The major PARADIGM?HF criteria were applied, and 95 patients fulfilled all enrolment criteria and thus were eligible for sacubitril?valsartan. This corresponds to 5% of the overall heart failure population and 24% of the population with ejection fraction ? 35%. The eligible patients were significantly older (73.2 ± 10.3 vs. 63.8 ± 11.5 years), had higher blood pressure (128 ± 17 vs. 122 ± 15 mmHg), had higher heart rate (77 ± 17 vs. 72 ± 12 b.p.m.), and had more atrial fibrillation (51.6% vs. 36.2%) than did the PARADIGM?HF population. Conclusions: Only 24% of our real?world heart failure and reduced ejection fraction population was eligible for sacubitril?valsartan, and the real?world heart failure and reduced ejection fraction patients were significantly older than the PARADIGM?HF population. The lack of data on a majority of the patients that we see in clinical practice is a real problem, and we are limited to extrapolation of results on a slightly different population. This is difficult to address, but perhaps registry?based randomized clinical trials will help to solve this issue. Twit Text FOAVip Eligibility of sacubitril valsartan in a real world heart failure population: a community based single centre study ????ESC Heart Fail http://www.kidney.de/pget.php?&tw=1&pmid=29345425 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29345425 #FOAvip English Wikipedia <ref>{{Cite pmid|29345425}}</ref> Eligibility of sacubitril?valsartan in a real?world heart failure population: a community?based single?centre study #MMPMID29345425 Norberg H; Bergdahl E; Lindmark K ESC Heart Fail 2018[Apr]; 5 (2): 337-43 PMID29345425show ga Aims: This study aims to investigate the eligibility of the Prospective Comparison of Angiotensin Receptor?Neprilysin Inhibitor (ARNI) with ACE inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM?HF) study to a real?world heart failure population. Methods and results: Medical records of all heart failure patients living within the catchment area of Umeå University Hospital were reviewed. This district consists of around 150 000 people. Out of 2029 patients with a diagnosis of heart failure, 1924 (95%) had at least one echocardiography performed, and 401 patients had an ejection fraction of ?35% at their latest examination. The major PARADIGM?HF criteria were applied, and 95 patients fulfilled all enrolment criteria and thus were eligible for sacubitril?valsartan. This corresponds to 5% of the overall heart failure population and 24% of the population with ejection fraction ? 35%. The eligible patients were significantly older (73.2 ± 10.3 vs. 63.8 ± 11.5 years), had higher blood pressure (128 ± 17 vs. 122 ± 15 mmHg), had higher heart rate (77 ± 17 vs. 72 ± 12 b.p.m.), and had more atrial fibrillation (51.6% vs. 36.2%) than did the PARADIGM?HF population. Conclusions: Only 24% of our real?world heart failure and reduced ejection fraction population was eligible for sacubitril?valsartan, and the real?world heart failure and reduced ejection fraction patients were significantly older than the PARADIGM?HF population. The lack of data on a majority of the patients that we see in clinical practice is a real problem, and we are limited to extrapolation of results on a slightly different population. This is difficult to address, but perhaps registry?based randomized clinical trials will help to solve this issue. äEligibility of sacubitril?valsartan in a real?world heart failure popu(epmc).pdf DeepDyve Pubget Overpricing